Evidence map›Paper›PMID 40299025›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Combining computational and experimental approaches: a novel pH-responsive PVA-stabilized MXene nanocarriers/doxorubicin delivery system with enhanced efficacy for targeted lung cancer therapeutics.

Shan Fang, Yuan Li, Wenjuan Wu, Kun He, Nagaraj Patil, Shubham Sharma, Karthikeyan A, Dhirendra Nath Thatoi, Azath Mubarakali

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shan FangDepartment of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Road, Wuhan City, Hubei Province, 430022, China.
Yuan LiDepartment of Respiratory Medicine, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, China.
Wenjuan WuDepartment of Medical Oncology, The First Affiliated Hospital of Hebei North University, No.36, Changqing District, Zhangjiakou, 075000, China.
Kun HeDepartment of Emergency, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China. hekun060708@hotmail.com.
Nagaraj PatilDepartment of Mechanical Engineering, School of Engineering and Technology, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Shubham SharmaDepartment of Technical Sciences, Western Caspian University, Baku, Azerbaijan.
Karthikeyan ADepartment of Mechanical Engineering, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.ORCID http://orcid.org/0000-0003-0435-9822
Dhirendra Nath ThatoiDepartment of Mechanical Engineering, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751030, India.ORCID http://orcid.org/0000-0002-2633-4805
Azath MubarakaliDepartment of Informatics and Computer Systems, College of Computer Science, King Khalid University, Abha, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While advancements have been made in cancer treatment, achieving effective localized therapy remains a significant challenge. Major obstacles include the inefficiency of drug delivery methods and the side effects linked to traditional chemotherapeutics. In this study, we present an innovative delivery system designed to transport doxorubicin (DOX) directly to the lungs. This system employs PVA-stabilized DOX-loaded MXene, aiming to improve targeted delivery and drug efficacy while minimizing toxicity. Our approach represents a promising advancement in the optimization of cancer therapeutics. Using in silico and computational methods, we evaluated the interactions between PVA, DOX, and MXene. Characterization techniques demonstrated that the synthesized PVA@Mxene/DOX exhibited favorable physicochemical properties. We assessed the anticancer potential of PVA@Mxene/DOX through the MTT assay, in vitro migration assay, and apoptosis assay. The findings revealed that the developed anticancer PVA@Mxene/DOX displayed a layered structure with controlled release kinetics. Notably, it significantly reduced cancer cell growth (P < 0.05), induced apoptosis in cancer cells, and inhibited their migration. These results suggest that PVA@Mxene/DOX holds promise as an effective anticancer agent to enhance lung cancer treatment and improve patient care.

Indexed as

Antibiotics, AntineoplasticDoxorubicinDrug CarriersLung NeoplasmsNanoparticlesPolyvinyl AlcoholA549 CellsAntineoplastic AgentsApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalDrug Delivery SystemsDrug LiberationHumansAntibiotics, AntineoplasticAntineoplastic AgentsDoxorubicinDrug CarriersMXeneNitritesPolyvinyl AlcoholTransition ElementsChemotherapeutic engineeringLung cancer treatmentNursing care

Identifiers

PMID40299025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.